BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24675486)

  • 21. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
    Liang X; Guo L; Hu X; Li S; Wen S
    Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
    Chihara D; Pro B; Loghavi S; Miranda RN; Medeiros LJ; Fanale MA; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Neelapu SS; Younes A; Fowler NH; Rodriguez MA; Wang M; Kwak LW; McLaughlin P; Dang NH; Oki Y
    Br J Haematol; 2015 Nov; 171(4):509-16. PubMed ID: 26260306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.
    Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K
    Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
    Kitahara H; Maruyama D; Maeshima AM; Makita S; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Terauchi T; Kurihara H; Taniguchi H; Komatsu N; Tobinai K
    Ann Hematol; 2017 Mar; 96(3):411-420. PubMed ID: 27928587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical characteristics and survival of peripheral T-cell lymphoma-not otherwise specified: a report of 57 cases].
    Chen X; Dong DF; Wu YY; Huang HY; Liang J; Li EX
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):916-9. PubMed ID: 20193331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
    Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
    Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
    Zheng W; Zhu J; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
    [No Abstract]   [Full Text] [Related]  

  • 36. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Miyashita K; Fujisawa S; Ogusa E; Matsuura S; Kishimoto K; Numata A; Fujita A; Ohshima R; Kuwabara H; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Fujimaki K; Taguchi J; Sakai R; Ishigatsubo Y
    Br J Haematol; 2013 May; 161(3):383-8. PubMed ID: 23432318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.